» Articles » PMID: 1086883

Allogeneic Carrier-specific Enhancement of Hapten-specific Secondary B-cell Responses

Overview
Journal J Exp Med
Date 1976 Nov 2
PMID 1086883
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

We have analyzed the capacity of carrier-specific T cells to enhance the immune response of hapten-specific secondary B cells which do not share genes in the H-2 complex with the T cells. For this analysis we have used the in vitro splenic focus technique which allows assessment of monoclonal responses of B cells isolated in splenic fragment cultures of irradiated reconstituted carrier primed mice. A previous report from this laboratory demonstrated that syngeny in the I region of the H-2 complex was necessary between collaborating hapten-specific primary (nonimmune) B cells and carrier-specific T cells for responses yielding IgG1 but not IgM antibody. These findings lead up to postulate that the expression of I-region gene products on the surface of primary B cells and I-region syngeny with collaborating carrier-specific T cells were essential elements in the triggering events leading to IgG1 synthesis by primary B cells. The results presented in the present report indicate that, unlike primary B cells, the majority of secondary B cells can be stimulated to produce IgG1 antibody in carrier-primed allogeneic recipients. Although the enhancement of secondary IgG1 responses is slightly greater with syngeneic T cells, the allogeneic collaborative interaction requires both carrier priming of recipient mice and stimulation with the homologous hapten-carrier complex and thus appears to be specific. These findings clearly discriminate secondary from primary B cells and indicate that the mechanism of stimulation of secondary B cells to yield IgG1-producing clones differs fundamentally from the stimulation of primary B cells in that the requisite for I-region syngeny is obviated.

Citing Articles

16 Methods for Detecting Microbial Pathogens in Food and Water.

Kaspar C, Tartera C Methods Microbiol. 2024; 22:497-531.

PMID: 38620159 PMC: 7148849. DOI: 10.1016/S0580-9517(08)70253-8.


A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.

Arnon R, Tarrab-Hazdai R, Steward M Immunology. 2000; 101(4):555-62.

PMID: 11122460 PMC: 2327114. DOI: 10.1046/j.1365-2567.2000.00139.x.


Acetylcholinesterase from Schistosoma mansoni: interaction of globular species with heparin.

Tarrab-Hazdai R, Toker L, Silman I, Arnon R Biochem J. 1999; 344 Pt 3:945-51.

PMID: 10585885 PMC: 1220720.


Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni.

Tarrab-Hazdai R, Schechtman D, Arnon R Infect Immun. 1998; 66(9):4526-30.

PMID: 9712813 PMC: 108551. DOI: 10.1128/IAI.66.9.4526-4530.1998.


Immunological features of psoriasis. Effects of Ro-109359, concanavalin A, pokeweed mitogen, and methotrexate on cultivated lymphocytes.

Bialasiewicz A, Lubach D, MARGHESCU S Arch Dermatol Res. 1981; 271(1):29-40.

PMID: 7294881 DOI: 10.1007/BF00417385.


References
1.
Benacerraf B, McDevitt H . Histocompatibility-linked immune response genes. Science. 1972; 175(4019):273-9. DOI: 10.1126/science.175.4019.273. View

2.
Askenase P, Leonard E . Solid phase radioimmunoassay of human beta 1C globulin. Immunochemistry. 1970; 7(1):29-41. DOI: 10.1016/0019-2791(70)90028-5. View

3.
Bach F, Segall M, Zier K, Sondel P, Alter B, Bach M . Cell mediated immunity: separation of cells involved in recognitive and destructive phases. Science. 1973; 180(4084):403-6. DOI: 10.1126/science.180.4084.403. View

4.
Klinman N, Pickard A, Sigal N, Gearhart P, Metcalf E, Pierce S . Assessing B cell diversification by antigen receptor and precursor cell analysis. Ann Immunol (Paris). 1976; 127(3-4):489-502. View

5.
Strober S . Immune function cell surface characteristics and maturation of B cell subpopulations. Transplant Rev. 1975; 24:84-112. DOI: 10.1111/j.1600-065x.1975.tb00166.x. View